Manchester-based Lydall Inc.’s bioscience-packaging division won approval from federal regulators to market a new type of biocontainer that drug makers and other health researchers can use to safely store and transport frozen stem cells.
Lydall CEO Dale Barnhart said Charter Medical Ltd., based in Winston-Salem, N.C., said the Food and Drug Administration approved the containers which were designed “side by side with our customers.”
Marketing of the containers sized from 50 to 750 milliliters will begin immediately, Barnhart said.
News of the FDA’s approval of its cryogenic stem cell containers comes just days after Lydall disclosed the resignation of Peter V. Ferris as Charter Medical president.
Charter also produces biofilters, blood and cell transfusion bags and other sterile biocontainers. Â
Lydall also produces materials used in automotive air and oil filters and for sound and thermal insulation.
